Want Actavis? Prepare to pay up, CEO says

Carly Helfand Actavis CEO Brent Saunders expects pharma's deal wave to continue. But make no mistake, he says: Potential suitors are going to have to pony up a pretty penny if they ...

Activists want Ariad’s CEO out the door, report says

Damian Garde A year after taking a seat on Ariad Pharmaceuticals' board, activist investor Alex Denner is looking to oust CEO Harvey Berger, CNBC reports. FierceBiotech News

Shire set to grow in 2015, but don’t expect a repeat of last year, it says

Carly Helfand Shire has some hefty sales forecasts in place for 2020, when CEO Flemming Ornskov has said it'll be bringing in a $ 10 billion top-line haul. Now, after a monster ...

Shooting for $5B in sales, India’s Lupin says it can actually hit U.S. launch goal this year

EJ Lane SINGAPORE–Despite missing its target for bringing 15 to 20 drugs to the U.S. market last year, Lupin is optimistic enough about 2015 that it seeks possible acquisitions ...

Look for a new Sanofi CEO by March, says chairman, as earnings top forecast

Tracy Staton Striking out in our CEO search? Not us, says Sanofi. Chairman Serge Weinberg says the board is talking to a "limited number of candidates" and expects to make ...

Sanofi’s finally going to name a new CEO, chairman says

Damian Garde Sanofi will announce its new chief executive by the end of March, the drugmaker's chairman said, ending months of speculation and reported recruitment failure. FierceBiotech ...

Cost-cutting, check. Now, it’s on to dealmaking, Teva chief says

Carly Helfand Teva is ready to make some deals now. It's a mantra that's seen quite a bit of play since CEO Erez Vigodman took up the reins at the generics giant early last ...

Strong earnings suggest Allergan sold too cheap, analyst says

Carly Helfand Allergan's fourth-quarter and full-year financials are out, and the way Bernstein analyst Ronny Gal sees it, based on the company's performance, it "should ...

Sanofi Chairman says French tax burden a killer for attracting execs

Eric Palmer Sanofi Chairman Serge Weinberg, who must replace Chris Viehbacher after ousting the outspoken CEO, has publicly expressed his own exasperation with France, saying its high ...

EMA, like FDA, says testosterone-raising drugs are not for lifestyle use

Eric Palmer The European Medicines Agency has thrown more cold water on sales of testosterone-raising meds as a party drug for aging men. The agency said today that the evidence is ...

Actavis bid looms as Allergan says it’s been approached (again) on merger

John Carroll Allergan today confirmed what much of the industry has been buzzing about for some time now: It's in takeover discussions with another company other than the acquisition-hungry ...

Zilmax is safe, Merck says. But will the meat industry buy it?

Carly Helfand When it comes to cattle feed additive Zilmax, pulled from the market last year on concerning side-effect reports, there's nothing to worry about, Merck says. After ...
Page 3 of 812345...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS